Biopharmas raising money in public or private financings, including: Biophytis, Celsion, Elevation, GH Research, Inhibikase, Kempharm, Monte Rosa, Protagonist, Rapt.
CAR T specialist Carsgen Therapeutics Holdings Ltd.’s shares started trading on the Hong Kong Stock Exchange on June 18, helping the company raise HK$3.1 billion (US$400 million) from an IPO that will allow it to advance its phase II-stage BCMA CAR T therapy candidate, CT-053, in multiple markets.
Biopharmas raising money in public or private financings, including: Alzamend, Ambrx, Anacardio, Atai, Century, Cyteir, Hutchmed, Karolinska, Neuvocor, PDS.
Kahr Medical Ltd.’s $46.5 million financing provides runway to advance its multifunctional immunotherapeutic pipeline. The proceeds will be used to for clinical development of its lead asset, DSP-107, a first-in-class CD47x41BB targeting fusion protein to treat solid tumors and blood cancers through multiple phase I/II studies.
Apollo Therapeutics LLC has completed a $145 million financing to develop its business model, based on building a portfolio of drugs through relationships with U.K. academic institutions.
Mindup, an Israeli digital health incubator, added Phenofast Ltd. to its portfolio this week, banking on the startup’s ability to resolve a critical, ongoing problem for hospitals and community physicians treating patients with urinary tract infections (UTIs). Phenofast hopes to bring clarity to antimicrobial susceptibility testing (AST) and relief to patients in record time.
Fractyl Health Inc. closed $100 million in new financing Wednesday to expand and accelerate clinical development efforts to reduce dependence on insulin among type 2 diabetes patients. The startup, which changed its name from Fractyl Laboratories Inc., will use the financing to support additional late-stage clinical studies for determining the potential of its Revita DMR.
RSS
